Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of BALI Association for Aphthous Ulcerations
NCT05542173Phase 3Not yet recruiting
- Sponsor
- EMS
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bismuth sodium tartrate, neomycin and procaine in aphthous stomatitis (RAS) (2 arms), sponsored by EMS. Primary endpoint: Reduction in pain intensity after 3 days of treatment. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
bismuth sodium tartrateneomycinprocaine
03
Conditions
aphthous stomatitis (RAS)
Beyond the preview
Go deeper on NCT05542173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05542173.